Literature DB >> 8345407

An immunohistological study of cutaneous lymphocytes in vitiligo.

A M Badri1, P M Todd, J J Garioch, J E Gudgeon, D G Stewart, R B Goudie.   

Abstract

In a study of 49 biopsies from the margins of depigmented cutaneous lesions in 18 patients with vitiligo, highly significant overall increases were found in CD3+, CD4+, and CD8+ T cells, though cell numbers in individual cases were often within the normal range. Many of the T cells were activated (MHC class II+, interferon gamma+), of CD45RO (UCHL1+) memory subset, and many expressed the cutaneous lymphocyte-associated antigen (HECA-452+) typical of skin-homing T cells. Immunohistologically, the most intense epidermal T-cell infiltration was present within 0.6 mm of the edge of the lesion in 10 of 13 double-stained sections with a clearly defined zone of melanocyte depletion. In 40 lesions from 17 patients seen 11-64 weeks after biopsy, no apparent association was found between T-cell numbers and disease activity as assessed by Köbnerization of biopsy wounds or spread of depigmentation. These findings are consistent with the hypothesis that lesional T cells rather than circulating antimelanocytic antibody may be responsible for the supposedly autoimmune but characteristically patchy destruction of cutaneous melanocytes in vitiligo. Nevertheless, many of the infiltrating T cells are probably innocent bystanders attracted by upregulated cell adhesion molecules near sites of melanocyte damage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345407     DOI: 10.1002/path.1711700209

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  32 in total

Review 1.  Hypopigmentary skin disorders: current treatment options and future directions.

Authors:  Anke Hartmann; Eva-B Bröcker; Jürgen C Becker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease.

Authors:  Richard A Spritz
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

3.  Epidermal permeability barrier recovery is delayed in vitiligo-involved sites.

Authors:  J Liu; W Y Man; C Z Lv; S P Song; Y J Shi; P M Elias; M Q Man
Journal:  Skin Pharmacol Physiol       Date:  2010-02-25       Impact factor: 3.479

Review 4.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 5.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

Review 6.  New treatment modalities for vitiligo: focus on topical immunomodulators.

Authors:  Kresimir Kostovic; Aida Pasic
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Functional melanocytes derived from human pluripotent stem cells engraft into pluristratified epidermis.

Authors:  Xavier Nissan; Lionel Larribere; Manoubia Saidani; Ilse Hurbain; Cédric Delevoye; Jessica Feteira; Gilles Lemaitre; Marc Peschanski; Christine Baldeschi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-19       Impact factor: 11.205

Review 8.  The convergence theory for vitiligo: A reappraisal.

Authors:  Roopal V Kundu; Julia M Mhlaba; Stephanie M Rangel; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2018-06-28       Impact factor: 3.960

9.  CTLA-4 A49G gene polymorphism is not associated with vitiligo in South Indian population.

Authors:  Farha Deeba; Rabbani Syed; Jariya Quareen; M A Waheed; Kaiser Jamil; Hanmanth Rao
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

Review 10.  5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.